Have arrived at the next step in commercialisation of our #ProstateCancer diagnostic, offering US urologists another tool to inform treatment decisions & at-risk men better diagnosis in Q2 this year. Looking forward to a great partnership with Cirrus Dx https://t.co/2Wcfq2c1u8
After winning 1st prize in the recent Innovation & Entrepreneurship Competition for Overseas Talents 2018, which was held in Sydney, our CEO @drbrad69 Walsh is excited to be heading to @Hangzhou_CHINA to compete in the final round.
Another great meeting @AustProstate 19th Asia-Pacific Prostate Cancer Conference in Brisbane. Good to meet up with our friend and colleague Prof Dan Chan and to be able to present the data from Minomic International Ltd Miltuximab study
#apcc18#men#ProstateCancer#urology
Thanks to Howard Gurney, Dhanusha Saba Macquarie University Hospital ANSTO Auspep and Macquarie Medical Imaging for their great teamwork with Minomic International Ltd in achieving this truly outstanding result https://t.co/wNXXItRrmm
So pleased we bring together our clinical, regulatory, trial & business advisors around the #AUA18 in #SF & #StHelena. Thanks to @Urogill, Neal Shore, @EmbertonMark, Dan Chan, Maria Chan, @gpalapa2, John Cullity, Tom Paivanas, Arletta van Breda for your contribute to @MinomicInt
#Minomic completes Prospective Clinical Study using #MiCheck to assist in diagnosis of #ProstateCancer. •58% Fewer patients proceed to Biopsy •US Rollout well advanced https://t.co/5BNkABrR7d
Pleasure to host both our local member @JAforBennelong and Assistant Minister @ZedSeselja@MinomicInt today to discuss our solutions for #prostatecancer diagnosis and therapy
Dr Doug Campbell presenting on Glypican-1 as a new target in CaP. Minomic’s @MinomicInt work with Dr Ganesh Palapattu @gpalapa2 and Dr Hans Klingemann @NantKwest